Misplaced Pages

Lentinan: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 08:29, 18 September 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:← Previous edit Latest revision as of 22:19, 2 December 2023 edit undoOAbot (talk | contribs)Bots441,761 editsm Open access bot: doi updated in citation with #oabot. 
(68 intermediate revisions by 36 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Drugbox {{Drugbox
| Verifiedfields = changed
| verifiedrevid = 447925816
| verifiedrevid = 451110455
| IUPAC_name = β-<small>D</small>-glucopyranosyl-(1&rarr;6)--β-<small>D</small>-glucopyranosyl-(1&rarr;3)-β-<small>D</small>-glucopyranosyl-(1&rarr;3)β-<small>D</small>-glucopyranosyl-(1&rarr;3)]-β-<small>D</small>-glucopyranose
| IUPAC_name =
| image = Lentinan.svg | image = Lentinan.svg
| width = 400px | width = 300px
<!-- Clinical data -->

<!--Clinical data-->
| tradename = | tradename =
| Drugs.com = {{drugs.com|international|lentinan}} | Drugs.com = {{drugs.com|international|lentinan}}
Line 16: Line 17:
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = | legal_status =
| routes_of_administration = | routes_of_administration =
<!-- Pharmacokinetic data -->

<!--Pharmacokinetic data-->
| bioavailability = | bioavailability =
| protein_bound = | protein_bound =
| metabolism = | metabolism =
| elimination_half-life = | elimination_half-life =
| excretion = | excretion =
<!-- Identifiers -->

| CAS_number_Ref = {{cascite|correct|??}}
<!--Identifiers-->
| CAS_number = 37339-90-5 | CAS_number = 37339-90-5
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 6751655D1D
| ATC_prefix = L03 | ATC_prefix = L03
| ATC_suffix = AX01 | ATC_suffix = AX01
| PubChem = 37723 | ChEBI = 31770
| PubChem =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = | DrugBank =
| KEGG_Ref = {{keggcite|correct|kegg}} | KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01695 | KEGG = D01695
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none
<!--Chemical data-->
<!-- Chemical data -->
| C=42 | H=72 | O=36
| molecular_weight = 1152.99948 g/mol | molecular_weight = ~ 500,000 Da
| synonyms =
| synonyms = <small>(2''S'',3''R'',4''S'',5''S'',6''R'')-2-oxymethyl]oxan-4-yl]oxyoxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-<nowiki>oxymethyl]oxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol</small>
}} }}


'''Lentinan''' is a ] isolated from the ] of ] mushroom (''Lentinula edodes'').
'''Lentinan''' is a ] with a glycosidic β-1,3:β-1,6 linkage.<ref name="CancerGuide"> Includes many abstracts</ref> It is an anti-tumor ] from the ] (''Lentinula edodes'') mushroom.<ref name="CancerGuide"/> Lentinan is a polysaccharide that has a molecular weight of approximately 500,000 Da. The Japanese pharmaceutical company ] developed Lentinan, which is an intravenously administered anti-cancer agent.


==Chemistry==
Lentinan is one of the host-mediated anti-cancer drugs<ref name="pmid10522061">{{cite journal| author=Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K| title=A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group. | journal=Hepatogastroenterology | year= 1999 | volume= 46 | issue= 28 | pages= 2662–8 | pmid=10522061 | doi= | pmc= | url= }} </ref> which has been shown to affect host defense immune systems.<ref>{{cite journal |author=Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K |title=A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group |journal=Hepatogastroenterology |volume=46 |issue=28 |pages=2662–8 |year=1999 |pmid=10522061 |doi=}}</ref>
Lentinan is a β-1,3 ] with β-1,6 branching. It has a molecular weight of 500,000 Da and specific rotation of +14-22° (NaOH).


==Research into the effects of Lentinan== ==Research==
===Preclinical studies===
Lentinex is a formulation featuring lentinan and is approved for use in the EU. An '']'' experiment showed lentinan stimulated production of white blood cells in the human cell line ].<ref name="pmid = 10190187 ">
An '']'' experiment showed lentinan stimulated production of white blood cells in the human cell line ].<ref name="pmid = 10190187 ">{{cite journal | vauthors = Sia GM, Candlish JK | title = Effects of shiitake (Lentinus edodes) extract on human neutrophils and the U937 monocytic cell line | journal = Phytotherapy Research | volume = 13 | issue = 2 | pages = 133–137 | date = March 1999 | pmid = 10190187 | doi = 10.1002/(SICI)1099-1573(199903)13:2<133::AID-PTR398>3.0.CO;2-O | doi-access = free }}</ref> Lentinan is thought to be inactive in humans when given orally and is therefore administered intravenously. The authors of an '']'' study of lentinan suggested that the compound may be active when administered orally in mice.<ref name="pmid = 12470439">{{cite journal | vauthors = Ng ML, Yap AT | title = Inhibition of human colon carcinoma development by lentinan from shiitake mushrooms (Lentinus edodes) | journal = Journal of Alternative and Complementary Medicine | volume = 8 | issue = 5 | pages = 581–589 | date = October 2002 | pmid = 12470439 | doi = 10.1089/107555302320825093 }}</ref>
{{Cite journal
| author = Sia GM, Candlish JK.
| title = Effects of shiitake (Lentinus edodes) extract on human neutrophils and the U937 monocytic cell line.
| journal = Phytother Res.
| volume = 13
| issue = 2
| pages = 133–7
| publisher =
| location =
| year = 1999
| month = Mar
| doi = 10.1002/(SICI)1099-1573(199903)13:2<133::AID-PTR398>3.0.CO;2-O
| pmid = 10190187
| postscript = <!--None-->
}}</ref>
A pharmacological blend (]) of lentinan, ], '']'' and '']'' has also been shown to stimulate white blood cell production ''in vitro''. <ref>
{{Cite journal
| author = Clark D, Adams M.
| title = Using commercial nutraceutical mixes as immune stimulants: an in vitro proliferation study using Metabolic Cell-Support on non-stimulated human lymphocytes.
| journal = Austr. J. Med. Herbal.
| volume = 19
| pages = 108–111
| year = 2007
| postscript = <!--None-->
}}</ref>


===Human clinical trials===
An '']'' experiment on mice, revealed lentinan is orally active (since clinical use of the drug is administered through an IV). <ref name="pmid = 12470439">
Lentinan has been the subject of a limited number of clinical studies in cancer patients in Japan;<ref name="pmid = 18670743">{{cite journal | vauthors = Yang P, Liang M, Zhang Y, Shen B | title = Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC | journal = Advances in Therapy | volume = 25 | issue = 8 | pages = 787–794 | date = August 2008 | pmid = 18670743 | doi = 10.1007/s12325-008-0079-x | s2cid = 33140754 | doi-access = free }}</ref><ref name="pmid = 16897983">{{cite journal | vauthors = Nimura H, Mitsumori N, Takahashi N, Kashimura H, Takayama S, Kashiwagi H, Yanaga K | title = | language = ja | journal = Gan to Kagaku Ryoho. Cancer & Chemotherapy | volume = 33 Suppl 1 | issue = 1 | pages = 106–109 | date = June 2006 | pmid = 16897983 }}</ref><ref name="pmid = 10522061">{{cite journal | vauthors = Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K | title = A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group | journal = Hepato-Gastroenterology | volume = 46 | issue = 28 | pages = 2662–2668 | year = 1999 | pmid = 10522061 }}</ref><ref name="pmid19596954">{{cite journal | vauthors = Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J | title = Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer | journal = Anticancer Research | volume = 29 | issue = 7 | pages = 2739–2745 | date = July 2009 | pmid = 19596954 }}</ref><ref name="pmid19596936">{{cite journal | vauthors = Hazama S, Watanabe S, Ohashi M, Yagi M, Suzuki M, Matsuda K, Yamamoto T, Suga Y, Suga T, Nakazawa S, Oka M | display-authors = 6 | title = Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer | journal = Anticancer Research | volume = 29 | issue = 7 | pages = 2611–2617 | date = July 2009 | pmid = 19596936 | url = http://ar.iiarjournals.org/content/29/7/2611.full }}</ref><ref name="pmid19579640">{{cite journal | vauthors = Kataoka H, Shimura T, Mizoshita T, Kubota E, Mori Y, Mizushima T, Wada T, Ogasawara N, Tanida S, Sasaki M, Togawa S, Sano H, Hirata Y, Ikai M, Mochizuki H, Seno K, Itoh S, Kawai T, Joh T | display-authors = 6 | title = Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life | journal = Hepato-Gastroenterology | volume = 56 | issue = 90 | pages = 547–550 | year = 2009 | pmid = 19579640 }}</ref><ref name="pmid19579616">{{cite journal | vauthors = Isoda N, Eguchi Y, Nukaya H, Hosho K, Suga Y, Suga T, Nakazawa S, Sugano K | display-authors = 6 | title = Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma | journal = Hepato-Gastroenterology | volume = 56 | issue = 90 | pages = 437–441 | year = 2009 | pmid = 19579616 }}</ref><ref name="pmid19453066">{{cite journal | vauthors = Shimizu K, Watanabe S, Watanabe S, Matsuda K, Suga T, Nakazawa S, Shiratori K | title = Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer | journal = Hepato-Gastroenterology | volume = 56 | issue = 89 | pages = 240–244 | year = 2009 | pmid = 19453066 }}</ref> however, evidence of ] is lacking.<ref name="webmd">{{cite web|title=Lentinan|url=http://www.webmd.com/vitamins-supplements/ingredientmono-763-lentinan.aspx?activeingredientid=763&activeingredientname=lentinan|publisher=]|access-date=June 10, 2017}}</ref><ref name="MSKCC">{{cite web|title=Lentinan|url=https://www.mskcc.org/cancer-care/integrative-medicine/herbs/lentinan|publisher=]|access-date=June 10, 2017}}</ref>
{{Cite journal
| author = Ng ML, Yap AT.
| title = Inhibition of human colon carcinoma development by lentinan from shiitake mushrooms (Lentinus edodes).
| journal = J Altern Complement Med.
| volume = 8
| issue = 5
| pages = 581–9
| publisher =
| location = National University of Singapore
| year = 2002
| month = Oct
| doi = 10.1089/107555302320825093
| pmid = 12470439
| postscript = <!--None-->
}}</ref>


===Adverse effects===
Limited clinical studies of cancer patients have associated lentinan with a higher survival rate, higher quality of life, and lower re-occurrence of cancer.<ref name="pmid = 18670743">
Lentinan has been reported to cause ].<ref name="Nakamura">{{cite journal | vauthors = Nakamura T | title = Shiitake (Lentinus edodes) dermatitis | journal = Contact Dermatitis | volume = 27 | issue = 2 | pages = 65–70 | date = August 1992 | pmid = 1395630 | doi = 10.1111/j.1600-0536.1992.tb05211.x | s2cid = 7320474 | doi-access = }}</ref>
{{Cite journal
| author = Yang P, Liang M, Zhang Y, Shen B.
| title = Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC.
| journal = Adv Ther.
| volume = 25
| issue = 8
| pages = 787–94
| publisher =
| location =
| year = 2008
| month = Aug
| doi = 10.1007/s12325-008-0079-x
| pmid = 18670743
| postscript = <!--None-->
}}</ref><ref name="pmid = 16897983">
{{Cite journal
| author = Nimura H, Mitsumori N, Takahashi N,
| title =
| journal = Gan to Kagaku Ryoho.
| volume = 33
| issue = 1
| pages = 106–9
| publisher =
| location =
| year = 2006
| month = Jun
| doi =
| pmid = 16897983
| issn =
| postscript = <!--None-->
}}</ref><ref name="pmid = 10522061">
{{Cite journal
| author = Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K.
| title = A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.
| journal = Hepatogastroenterology.
| volume = 46
| issue = 28
| pages = 2662–8
| publisher =
| location =
| year = 1999
| month =
| doi =
| pmid = 10522061
| issn =
| postscript = <!--None-->
}}</ref><ref name="pmid19596954">{{cite journal |author=Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J |title=Individual Patient Based Meta-analysis of Lentinan for Unresectable/Recurrent Gastric Cancer |journal=Anticancer Res. |volume=29 |issue=7 |pages=2739–45 |year=2009 |month=July |pmid=19596954 |doi= |url=}}</ref><ref name="pmid19596936">{{cite journal |author=Hazama S, Watanabe S, Ohashi M, ''et al.'' |title=Efficacy of Orally Administered Superfine Dispersed Lentinan ({beta}-1,3-Glucan) for the Treatment of Advanced Colorectal Cancer |journal=Anticancer Res. |volume=29 |issue=7 |pages=2611–7 |year=2009 |month=July |pmid=19596936 |doi= |url=}}</ref><ref name="pmid19579640">{{cite journal |author=Kataoka H, Shimura T, Mizoshita T, ''et al.'' |title=Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life |journal=Hepatogastroenterology |volume=56 |issue=90 |pages=547–50 |year=2009 |pmid=19579640 |doi= |url=}}</ref><ref name="pmid19579616">{{cite journal |author=Isoda N, Eguchi Y, Nukaya H, ''et al.'' |title=Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma |journal=Hepatogastroenterology |volume=56 |issue=90 |pages=437–41 |year=2009 |pmid=19579616 |doi= |url=}}</ref><ref name="pmid19453066">{{cite journal |author=Shimizu K, Watanabe S, Watanabe S, ''et al.'' |title=Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer |journal=Hepatogastroenterology |volume=56 |issue=89 |pages=240–4 |year=2009 |pmid=19453066 |doi= |url=}}</ref>


==See also== == See also ==
*] *]
*]
*Smith JE, Rowan NJ, Sullivan R ], 2001
*Memorial Sloan-Kettering Cancer Center's page for .


== References == == References ==
{{Reflist}} {{Reflist|30em}}


== External links == == External links ==
* effects (antitumor and others) * effects (antitumor and others)
*Memorial Sloan-Kettering Cancer Center's page for .




{{Immunostimulants}} {{Immunostimulants}}
{{Carbohydrates}} {{Carbohydrates}}

]
] ]
]


{{antineoplastic-drug-stub}}

]
]
]
]
]
]
]

Latest revision as of 22:19, 2 December 2023

Chemical compound Pharmaceutical compound
Lentinan
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass~ 500,000 Da
  (what is this?)  (verify)

Lentinan is a polysaccharide isolated from the fruit body of shiitake mushroom (Lentinula edodes).

Chemistry

Lentinan is a β-1,3 beta-glucan with β-1,6 branching. It has a molecular weight of 500,000 Da and specific rotation of +14-22° (NaOH).

Research

Preclinical studies

An in vitro experiment showed lentinan stimulated production of white blood cells in the human cell line U937. Lentinan is thought to be inactive in humans when given orally and is therefore administered intravenously. The authors of an in vivo study of lentinan suggested that the compound may be active when administered orally in mice.

Human clinical trials

Lentinan has been the subject of a limited number of clinical studies in cancer patients in Japan; however, evidence of efficacy is lacking.

Adverse effects

Lentinan has been reported to cause shiitake mushroom dermatitis.

See also

References

  1. Sia GM, Candlish JK (March 1999). "Effects of shiitake (Lentinus edodes) extract on human neutrophils and the U937 monocytic cell line". Phytotherapy Research. 13 (2): 133–137. doi:10.1002/(SICI)1099-1573(199903)13:2<133::AID-PTR398>3.0.CO;2-O. PMID 10190187.
  2. Ng ML, Yap AT (October 2002). "Inhibition of human colon carcinoma development by lentinan from shiitake mushrooms (Lentinus edodes)". Journal of Alternative and Complementary Medicine. 8 (5): 581–589. doi:10.1089/107555302320825093. PMID 12470439.
  3. Yang P, Liang M, Zhang Y, Shen B (August 2008). "Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC". Advances in Therapy. 25 (8): 787–794. doi:10.1007/s12325-008-0079-x. PMID 18670743. S2CID 33140754.
  4. Nimura H, Mitsumori N, Takahashi N, Kashimura H, Takayama S, Kashiwagi H, Yanaga K (June 2006). "". Gan to Kagaku Ryoho. Cancer & Chemotherapy (in Japanese). 33 Suppl 1 (1): 106–109. PMID 16897983.
  5. Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K (1999). "A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group". Hepato-Gastroenterology. 46 (28): 2662–2668. PMID 10522061.
  6. Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J (July 2009). "Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer". Anticancer Research. 29 (7): 2739–2745. PMID 19596954.
  7. Hazama S, Watanabe S, Ohashi M, Yagi M, Suzuki M, Matsuda K, et al. (July 2009). "Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer". Anticancer Research. 29 (7): 2611–2617. PMID 19596936.
  8. Kataoka H, Shimura T, Mizoshita T, Kubota E, Mori Y, Mizushima T, et al. (2009). "Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life". Hepato-Gastroenterology. 56 (90): 547–550. PMID 19579640.
  9. Isoda N, Eguchi Y, Nukaya H, Hosho K, Suga Y, Suga T, et al. (2009). "Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma". Hepato-Gastroenterology. 56 (90): 437–441. PMID 19579616.
  10. Shimizu K, Watanabe S, Watanabe S, Matsuda K, Suga T, Nakazawa S, Shiratori K (2009). "Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer". Hepato-Gastroenterology. 56 (89): 240–244. PMID 19453066.
  11. "Lentinan". WebMD. Retrieved June 10, 2017.
  12. "Lentinan". Memorial Sloan Kettering Cancer Center. Retrieved June 10, 2017.
  13. Nakamura T (August 1992). "Shiitake (Lentinus edodes) dermatitis". Contact Dermatitis. 27 (2): 65–70. doi:10.1111/j.1600-0536.1992.tb05211.x. PMID 1395630. S2CID 7320474.

External links

  • Lentinan effects (antitumor and others)
  • Memorial Sloan-Kettering Cancer Center's page for Lentinan.
Immunostimulants (L03)
Endogenous
Cytokines
Colony-stimulating factors
Interferons
Interleukins
Other protein / peptide
Other
Exogenous
Types of carbohydrates
General
Geometry
Monosaccharides
Dioses
Trioses
Tetroses
Pentoses
Hexoses
Heptoses
Above 7
Multiple
Disaccharides
Trisaccharides
Tetrasaccharides
Other
oligosaccharides
Polysaccharides
Categories: